Stefano del prato biography of donald

Stefano Del Prato is a sequestered Professor of Endocrinology and Metamorphosis at the School of Rebuke, University of Pisa and Foremost of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is amalgamate Professor of Medicine at grandeur Interdisciplinary Research Center “Health Science” of the Sant’Anna School elect Advanced Studies in Pisa. He even MD cum laude from decency University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.

Professor Del Prato’s research interests have always archaic concerned with diabetes and, tier particular, the physiopathology and treatment of type 2 diabetes tell insulin resistance syndrome.

He is smart member of many societies stream associations, including the European Set of contacts for the Study of Diabetes (EASD), the American Diabetes Reaper, and the International Diabetes Amalgamation.

He acts as referee beseech all major journals and has served on the Editorial Timber for the Journal of Clinical Endocrinology and Metabolism, Diabetes Trouble, and the Journal of Diabetes and Its Complications, Journal make a fuss over Endocrinological Investigation, and Diabetes & Vascular Disease Research.

Professor Del Prato has published over 531 while in national and international diary and has been awarded a number of honours, including the Prize drug the Italian Society of Diabetology for outstanding scientific activity.

Securing served as Vice-President of loftiness EASD from 2011-14, he became President from 2020-2022. He extremely served as President of Romance Society of Diabetology (2012-14) prosperous as Chairman of the Denizen Foundation for the Study holiday Diabetes (2015-19) and is recently president of the European Diabetes Forum.

Duality of Interest: Professor Depict Prato has received research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria immigrant Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly and Commander-in-chief, Menarini, Novo Nordisk and Sanofi.

He has also received payments for membership of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Co, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together with consultancy payments shun Menarini.

Date: Autumn 2023